» Articles » PMID: 29687175

Age-specific ALS Incidence: a Dose-response Meta-analysis

Overview
Journal Eur J Epidemiol
Specialty Public Health
Date 2018 Apr 25
PMID 29687175
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the association between worldwide ALS incidence rates and age, using a dose-response meta-analysis. We reviewed Medline and Embase up to July 2016 and included all population-based studies of newly-diagnosed cases, using multiple sources for case ascertainment. A dose-response meta-analysis was performed. A meta-regression investigated potential sources of heterogeneity. Of 3254 articles identified in the literature, we included 41 incidence studies covering 42 geographical areas. Overall, the fit between observed and predicted age-specific rates was very good. The expected variation of ALS incidence with age was characterized, in each study, by a progressive increase in the incidence from the 40s leading to a peak in the 60s or 70s, followed by a sharp decrease. Cochran's Q test suggested a significant heterogeneity between studies. Overall, estimated patterns of ALS age-specific incidence (at which the peak was reached) were similar among subcontinents of Europe and North America: peak of ALS incidence ranged in these areas between 6.98 and 8.17/100,000 PYFU, which referred to age in the range 71.6-77.4 years. The relationship between age and ALS incidence appeared different for Eastern Asia which was characterized by a peak of ALS incidence at 2.20/100,000 PYFU around 75 years of age. This study confirms the consistency of the age-specific ALS incidence pattern within different subcontinents. Age-specific incidence appears lower in Eastern Asia as compared to Europe and North America.

Citing Articles

Adverse events reporting of edaravone: a real-world analysis from FAERS database.

Shang Q, Zhou J, Ye J, Chen M Sci Rep. 2025; 15(1):8148.

PMID: 40059194 PMC: 11891309. DOI: 10.1038/s41598-025-92605-5.


Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population-Based Cohort Study.

Vaage A, Holmoy T, Dahl J, Stigum H, Meyer H, Nakken O Eur J Neurol. 2025; 32(3):e70095.

PMID: 40034089 PMC: 11876845. DOI: 10.1111/ene.70095.


Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.

PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.


Role of Rho-associated kinases and their inhibitor fasudil in neurodegenerative diseases.

Ye Q, Li X, Gao W, Gao J, Zheng L, Zhang M Front Neurosci. 2024; 18:1481983.

PMID: 39628659 PMC: 11613983. DOI: 10.3389/fnins.2024.1481983.


Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.

Yuan D, Jiang S, Xu R Ann Med. 2024; 56(1):2399962.

PMID: 39624969 PMC: 11616751. DOI: 10.1080/07853890.2024.2399962.


References
1.
Pugliatti M, Parish L, Cossu P, Leoni S, Ticca A, Saddi M . Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009. J Neurol. 2012; 260(2):572-9. DOI: 10.1007/s00415-012-6681-5. View

2.
Matsumoto N, WORTH R, Kurland L, Okazaki H . Epidemiologic study of amyotrophic lateral sclerosis in Hawaii. Identification of high incidence among Filipino men. Neurology. 1972; 22(9):934-40. DOI: 10.1212/wnl.22.9.934. View

3.
Cronin S, Hardiman O, Traynor B . Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007; 68(13):1002-7. DOI: 10.1212/01.wnl.0000258551.96893.6f. View

4.
Marin B, Boumediene F, Logroscino G, Couratier P, Babron M, Leutenegger A . Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2016; 46(1):57-74. PMC: 5407171. DOI: 10.1093/ije/dyw061. View

5.
Marin B, Hamidou B, Couratier P, Nicol M, Delzor A, Raymondeau M . Population-based epidemiology of amyotrophic lateral sclerosis (ALS) in an ageing Europe--the French register of ALS in Limousin (FRALim register). Eur J Neurol. 2014; 21(10):1292-300, e78-9. DOI: 10.1111/ene.12474. View